Thyroid Carcinoma, Anaplastic

"Thyroid Carcinoma, Anaplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.

Descriptor ID	D065646
MeSH Number(s)	C04.557.470.200.725
Concept/Terms	Thyroid Carcinoma, Anaplastic Thyroid Carcinoma, Anaplastic Anaplastic Thyroid Carcinoma Anaplastic Thyroid Carcinomas Carcinoma, Anaplastic Thyroid Carcinomas, Anaplastic Thyroid Thyroid Carcinomas, Anaplastic Thyroid Cancer, Anaplastic Anaplastic Thyroid Cancer Anaplastic Thyroid Cancers Cancer, Anaplastic Thyroid Cancers, Anaplastic Thyroid Thyroid Cancers, Anaplastic

Below are MeSH descriptors whose meaning is more general than "Thyroid Carcinoma, Anaplastic".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Glandular and Epithelial [C04.557.470]
Carcinoma [C04.557.470.200]
Thyroid Carcinoma, Anaplastic [C04.557.470.200.725]

Below are MeSH descriptors whose meaning is related to "Thyroid Carcinoma, Anaplastic".

Below are MeSH descriptors whose meaning is more specific than "Thyroid Carcinoma, Anaplastic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Thyroid Carcinoma, Anaplastic" by people in this website by year, and whether "Thyroid Carcinoma, Anaplastic" was a major or minor topic of these publications.

Bar chart showing 8 publications over 8 distinct years, with a maximum of 1 publications in 2011 and 2012 and 2013 and 2015 and 2018 and 2021 and 2022 and 2025

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2011	0	1	1
2012	0	1	1
2013	0	1	1
2015	1	0	1
2018	1	0	1
2021	1	0	1
2022	1	0	1
2025	1	0	1

Below are the most recent publications written about "Thyroid Carcinoma, Anaplastic" by people in Profiles.

Hartmann HA, Loberg MA, Xu GJ, Schwarzkopf AC, Chen SC, Phifer CJ, Caroland K, Chen HC, Diaz D, Tigue ML, Hesterberg AB, Gallant JN, Shaddy SM, Sheng Q, Netterville JL, Rohde SL, Sol?rzano CC, Bischoff LA, Baregamian N, Hurley PJ, Murphy BA, Choe JH, Huang EC, Ye F, Lee E, Weiss VL. Tenascin-C Potentiates Wnt Signaling in Thyroid Cancer. Endocrinology. 2025 Feb 05; 166(3).

View in: PubMed
Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 08; 20(8):925-951.

View in: PubMed
Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, Sherman SI, Bible KC, Robinson B, Rodien P, Godbert Y, De La Fouchardiere C, Newbold K, Nutting C, Misir S, Xie R, Almonte A, Ye W, Cabanillas ME. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. J Clin Oncol. 2021 07 20; 39(21):2359-2366.

View in: PubMed
Johnson JM, Chen J, Ali SM, Dardi IK, Tuluc M, Cognetti D, Campling B, Sama AR. Molecular Profiling of Synchronous Colon Cancers and Anaplastic Thyroid Cancer in a Patient with Lynch Syndrome. J Gastrointest Cancer. 2018 Jun; 49(2):203-206.

View in: PubMed
Johnson JM, Lai SY, Cotzia P, Cognetti D, Luginbuhl A, Pribitkin EA, Zhan T, Mollaee M, Domingo-Vidal M, Chen Y, Campling B, Bar-Ad V, Birbe R, Tuluc M, Martinez Outschoorn U, Curry J. Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer. Semin Oncol. 2015 Dec; 42(6):915-22.

View in: PubMed
Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R. Efatutazone, an oral PPAR-? agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013 Jun; 98(6):2392-400.

View in: PubMed
Dong X, Tang W, Stopenski S, Brose MS, Korch C, Meinkoth JL. RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells. Endocr Relat Cancer. 2012 Aug; 19(4):575-88.

View in: PubMed
Gopal PP, Montone KT, Baloch Z, Tuluc M, LiVolsi V. The variable presentations of anaplastic spindle cell squamous carcinoma associated with tall cell variant of papillary thyroid carcinoma. Thyroid. 2011 May; 21(5):493-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement